Brought to you by 
Biogen Idec buys Elan's share of Tysabri for $3.25bn plus royalties
22 Apr 2013
Executive Summary
Biogen Idec Inc. is paying $3.25bn in cash up front to acquire Elan Corp. PLC’s 50% share of the blockbuster multiple sclerosis drug Tysabri (natalizumab) and all related intellectual property.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen Idec buys Elan's share of Tysabri for $3.25bn plus royalties
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice